June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Efficacy of a New Tear Substitute Containing Hyaluronic Acid and a Low Dose of Hydrocortisone in Dry Eye Disease
Author Affiliations & Notes
  • Stefano Barabino
    Ophthalmology, Ocular Surface & Dry Eye Center, ASST Fatebenefratelli SACCO-University of Milan, Milan, Italy
  • Elena Vilella
    Ophthalmology, ASST Fatebenefratelli SACCO-University of Milan, Milan, Italy
  • Lara Loreggian
    Dipartimento di Scienze Biomediche e Cliniche “L. Sacco”, University of Milan,, International Center for T1D, Pediatric Clinical Research Center “Romeo ed Enrica Invernizzi”, Milan, Italy
  • Sara Marini
    Ophthalmology, ASST Fatebenefratelli SACCO-University of Milan, Milan, Italy
  • Cristian Loretelli
    Dipartimento di Scienze Biomediche e Cliniche “L. Sacco”, University of Milan,, International Center for T1D, Pediatric Clinical Research Center “Romeo ed Enrica Invernizzi”, Milan, Italy
  • Giorgio Alfredo Spedicato
    Università Cattolica del Sacro Cuore di Milano, Milan, Italy
  • Paolo Fiorina
    Dipartimento di Scienze Biomediche e Cliniche “L. Sacco”, University of Milan,, International Center for T1D, Pediatric Clinical Research Center “Romeo ed Enrica Invernizzi”, Milan, Italy
    Nephrology Division, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, United States
  • Maurizio Rolando
    Ocular Surface Center, Is.Pre Oftalmica, Genoa, Italy
  • Footnotes
    Commercial Relationships   Stefano Barabino, Oftalab (P); Elena Vilella, None; Lara Loreggian, None; Sara Marini, None; Cristian Loretelli, None; Giorgio Alfredo Spedicato, None; Paolo Fiorina, None; Maurizio Rolando, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 1253. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Stefano Barabino, Elena Vilella, Lara Loreggian, Sara Marini, Cristian Loretelli, Giorgio Alfredo Spedicato, Paolo Fiorina, Maurizio Rolando; Efficacy of a New Tear Substitute Containing Hyaluronic Acid and a Low Dose of Hydrocortisone in Dry Eye Disease. Invest. Ophthalmol. Vis. Sci. 2021;62(8):1253.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the effect of a new tear substitute containing hyaluronic acid (HA) and a low dose (0.001%) of hydrocortisone in patients with dry eye disease in a randomized, double-masked pilot study.

Methods : Dry eye and treatment outcomes were assessed by SANDE questionnaire, Schirmer I test, tear BUT, conjunctival staining by using a new formulation of liquid lissamine green, and fluorescein corneal staining (baseline, day 7 and 28). Immune cells (CD45+, CD14+, CD4+, CD8+) were detected by impression cytology and flow cytometry at baseline and day 28. All patients (n=40) received fluorometholone eye drops bid for one week. The study group used the new tear substitute (Idroflog, Alfa Intes, Italy) bid for one week and qid for three weeks; the control group used HA alone with the same regimen. Intraocular pressure (IOP) was recorded at baseline, day 7 and 28.

Results : Severity and frequency of symptoms were improved in both groups at day 7 and 28. Fluorescein and liquid lissamine green staining were significantly decreased at day 30 in the study group respect to the control (p≤ 0.05). No significant changes were recorded for Schirmer test and BUT. While CD45+ cells were decreased in both groups, CD14+ cells and the CD4/CD8 ratio significantly decreased in the study group only (p≤ 0.05). None of the treated eyes showed significant increase in IOP at day 28.

Conclusions : The results show the efficacy of a new a tear substitute to improve signs of dry eye, and to control inflammation over time. Further results are expected at a longer follow up (6 months), but the importance of chronic use of tear substitutes containing low percentage of steroids in dry eye seems to be demonstrated.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×